Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

The European Medicines Agency has approved Dupixent as the first treatment for eosinophilic esophagitis (EoE) in young children aged one to 11, m ...

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Furuta, Department of Pediatrics, Section of Pediatric Gastroenterology, Hepatology and Nutrition, The Children's Hospital ... no competing interests. Eosinophilic esophagitis is a ...

The 6-food elimination diet (SFED) is the most cost-effective first-line treatment for eosinophilic esophagitis (EoE) from a financial standpoint. However, proton pump inhibitors (PPIs) are the most ...

Eosinophilic esophagitis (EoE), a disorder of the esophagus, is increasingly recognized as a major cause of swallowing difficulties in children and adults. It affects about one in 2,000 people and ...

Countries facing conflict, natural disasters and humanitarian crises are struggling to provide routine childhood immunisations leaving many children vulnerable to the resurgence of polio, the UN ...